Zeriscope, a provider of mobile telemedicine examination systems, has been selected by the US Army Advanced Medical Technology Initiative (AAMTI) to assist in a study to mitigate the effects of Traumatic Brain Injury (TBI).
Zeriscope's real-time streaming telemedicine platform is being used along with its integrated wearable sensor kit to monitor heart rate variability (HRV), a biomarker associated with the ability to regulate the autonomic nervous system, attentiveness and emotional responses.
Using Zeriscope's wearable physiological devices, HRV can be monitored and studied in out-of-the-laboratory settings, improving research and the understanding of treatment options for this critical injury impacting so many who've served our country in combat zones.
"Zeriscope technology may facilitate more objective evaluation of treatment impact that can also be correlated with patient outcomes," said Dr. Michael Jenkins-Guarnieri, a TBI researcher at Madigan Army Medical Center. "Further, this technology could become a useful tool to evaluate novel treatment modalities in the future."
"We're very proud to have been selected by the Army to assist in this important and advanced research on traumatic brain injury," said Bill Harley, CEO of Zeriscope. "Zeriscope's easy to use and cost effect telemedicine technology is recognized as a smart solution for a broad variety of innovative telemedicine scenarios, leveraging remote medical experts anywhere, anytime."
The AAMTI study will last one year, and is designed to learn more about the effects of various treatment options that improve outcomes for those impacted by traumatic brain injury.